Meeting
2018 Palliative and Supportive Care in Oncology Symposium
Efficacy of intravenous (IV) NEPA, a fixed NK1/5-HT3 receptor antagonist combination, for prevention of emesis following highly emetogenic chemotherapy (HEC).
Authors
Eric Roeland
Massachusetts General Hospital, Boston, MA
Eric Roeland, Richard J. Gralla, Li Zhang, Paul Joseph Hesketh, Lee Steven Schwartzberg
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Advance Care Planning; Caregiver Support; Coordination and Continuity of Care; End-of-Life Care; Models of Care; Survivorship; and Symptom Biology, Assessment and Management
Track
Advance Care Planning,End-of-Life Care,Survivorship,Coordination and Continuity of Care,Symptom Biology, Assessment, and Management,Models of Care,Caregiver Support
Sub Track
Symptom Biology, Assessment, and Management
Clinical Trial Registration Number
NCT02517021
Citation
J Clin Oncol 36, 2018 (suppl 34; abstr 194)
DOI
10.1200/JCO.2018.36.34_suppl.194
Abstract #
194
Poster Bd #
E12
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Safety of intravenous (IV) NEPA and oral NEPA for prevention of CINV in patients (pts) with breast cancer (BC) receiving anthracycline/cyclophosphamide (AC) chemotherapy (CT).
First Author: Lee S. Schwartzberg
Poster
2017 Palliative and Supportive Care in Oncology Symposium
Phase III safety evaluation of intravenous NEPA, a novel fixed antiemetic combination of fosnetupitant and palonosetron, over multiple cycles.
First Author: Lee Steven Schwartzberg
Poster
2017 ASCO Annual Meeting
Phase III study of NEPA, a fixed combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV).
First Author: Li Zhang
Poster
2013 ASCO Annual Meeting
Efficacy of NEPA, a novel combination of netupitant (NETU) and palonosetron (PALO), for prevention of chemotherapy-induced nausea and vomiting (CINV) following highly emetogenic chemotherapy (HEC).
First Author: Paul Joseph Hesketh